166 related articles for article (PubMed ID: 37700492)
1. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
[TBL] [Abstract][Full Text] [Related]
2. High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons.
Bhandari R; Morey S; Hamoodi A; Thompson C; Jones D; Hewett M; Hunter E; Taha Y; McPherson S
J Viral Hepat; 2020 Apr; 27(4):449-452. PubMed ID: 31749225
[TBL] [Abstract][Full Text] [Related]
3. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
Morey S; Hamoodi A; Jones D; Young T; Thompson C; Dhuny J; Buchanan E; Miller C; Hewett M; Valappil M; Hunter E; McPherson S
J Viral Hepat; 2019 Jan; 26(1):101-108. PubMed ID: 30315691
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
5. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
6. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
[TBL] [Abstract][Full Text] [Related]
7. Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
Askar S; Jelley R; McQue K; Allsop C; McCullough F; Miller C; Taha Y; Masson S; McPherson S
J Viral Hepat; 2022 Aug; 29(8):685-690. PubMed ID: 35643915
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
10. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
11. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
[TBL] [Abstract][Full Text] [Related]
12. Consensus recommendations on the management of hepatitis C in Australia's prisons.
Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
[TBL] [Abstract][Full Text] [Related]
13. Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
Hibbert M; Simmons R; Harris H; Desai M; Sabin CA; Mandal S
J Viral Hepat; 2023 Aug; 30(8):646-655. PubMed ID: 36929670
[TBL] [Abstract][Full Text] [Related]
14. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C Virus Elimination Program among Prison Inmates, Israel.
Eisen L; Mor Z; Madar M; Rabinovitch R; Dadon Y; Sheffer R; Kaliner E; Goldstein L
Emerg Infect Dis; 2023 Nov; 29(11):2358-2361. PubMed ID: 37877627
[TBL] [Abstract][Full Text] [Related]
16. Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
Søholm J; Holm DK; Mössner B; Madsen LW; Hansen JF; Weis N; Sauer AP; Awad T; Christensen PB
PLoS One; 2019; 14(7):e0220297. PubMed ID: 31348813
[TBL] [Abstract][Full Text] [Related]
17. HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C.
Fiore V; De Matteis G; Ranieri R; Saderi L; Pontali E; Muredda A; Ialungo AM; Caruso R; Madeddu G; Sotgiu G; Babudieri S
Int J Drug Policy; 2021 Apr; 90():103055. PubMed ID: 33310637
[TBL] [Abstract][Full Text] [Related]
18. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
19. Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.
Snow KJ; Young JT; Preen DB; Lennox NG; Kinner SA
BMC Public Health; 2014 Aug; 14():830. PubMed ID: 25113132
[TBL] [Abstract][Full Text] [Related]
20. Reinfection with hepatitis C virus following sustained virological response in injection drug users.
Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B
J Gastroenterol Hepatol; 2010 Jul; 25(7):1281-4. PubMed ID: 20594256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]